TITLE

An exercise and behavioral management program reduced functional dependence in Alzheimer disease: COMMENTARY

AUTHOR(S)
Stott, David J.; Taylor, Morven
PUB. DATE
May 2004
SOURCE
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p77
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Many clinicians question the effectiveness of rehabilitation for patients with Alzheimer disease. Emphasis is often placed on introducing coping strategies, rather than active rehabilitation with the aim of improving physical function, mood, and behavior. Few good clinical trials exist on which to base clinical practice. No previous trial has been done of combined exercise and behavioral management in Alzheimer disease. The selection process in the study conducted, resulted in enrollment of about 40% of eligible patients and caregivers. The exercise and caregiver interventions are complex, but are clearly described and could be replicated. Validated outcome measures were used, with blinded observers. The statistical analyses are appropriate. The study is adequately powered to detect effects of the intervention on functional outcome, but is underpowered to detect any reduction in institutionalization.
ACCESSION #
13221856

 

Related Articles

  • An exercise and behavioral management program reduced functional dependence in Alzheimer disease.  // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p77 

    This article presents a study, which states that in patients with Alzheimer disease, a home-based exercise program combined with caregiver training in behavioral management techniques reduce functional dependence. 153 patients, who met criteria for probable or possible Alzheimer disease, were...

  • Alzheimer's Drug Approved.  // Medical Update;2003, Vol. 29 Issue 6, p7 

    Reports on the approval of Namenda, a class of drugs to treat moderate to severe cases of Alzheimer's disease, in the U.S. in December 2003. Results of clinical trials.

  • Dementia capital. O'Neill, Graeme // Bulletin with Newsweek;2/5/2002, Vol. 120 Issue 6310, p28 

    Reports on a breakthrough research that may point to a better treatment for Alzheimer's disease in Australia. Impact of the build-up of copper levels and amyloid deposits in the neocortex region of the brain; Use of a metal-chelating agent to melt away ameloid deposits; Other research findings.

  • Cholinesterase Inhibition for Alzheimer Disease. Qizilbash, Nawab; Whitehead, Anne; Higgins, Julian; Wilcock, Gordon; Schneider, Lon; Farlow, Martin // JAMA: Journal of the American Medical Association;11/25/98, Vol. 280 Issue 20, p1777 

    Presents a study to determine the effects of cholinesterase inhibition with tacrine hydrochloride for the symptoms of Alzheimer disease in terms of cognitive performance, clinical global impression, behavior, and functional autonomy.

  • Donepezil was no better than placebo for agitation in patients with Alzheimer disease. Van Reekum, Robert // ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p7 

    The article focuses on the randomized placebo-controlled trial investigating if Donepezil is better than placebo for clinically significant agitation that has not responded to psychosocial treatment in patients with Alzheimer disease. The trial, conducted with 259 patients (39 years of age),...

  • Promising trial results for Alzheimer's drug Reminyl.  // PharmaWatch: CNS;October 2004, Vol. 3 Issue 10, p8 

    The article presents information on promising trial results for Alzheimer's drug, Reminyl. A recent clinical trial has found that the Alzheimer's disease treatment, Reminyl, may improve the ability of patients to perform day-today activities. The study of the Janssen Pharmaceutical Products LP...

  • Trial disappointment for Forest Alzheimer's drug.  // PharmaWatch: CNS;October 2004, Vol. 3 Issue 10, p9 

    The article presents information about trial disappointment for Forest laboratories Inc.'s drug for Alzheimer's disease. Forest Laboratories' investigational Alzheimer's disease treatment neramexane is no more effective than current therapies for the condition, according to a recent clinical...

  • BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimer's Disease Therapies. Vassar, Robert // Current Medicinal Chemistry - Immunology, Endocrine & Metabolic ;Mar2003, Vol. 3 Issue 1, p47 

    A large (and still growing) body of evidence suggests that the �-amyloid peptide (A�) is central to the pathophysiology of Alzheimer's Disease (AD) and may in fact initiate disease processes that lead to this intractable neurodegenerative disorder. Amyloid plaques composed of A�...

  • The Medicinal Metallochemistry of Alzheimer's Disease. Cherny, Robert A.; Masters, Colin L.; Bush, Ashley I. // Current Medicinal Chemistry - Immunology, Endocrine & Metabolic ;Mar2003, Vol. 3 Issue 1, p9 

    The brain is an organ which is at once enriched in transition metals and highly susceptible to oxidative stress. By virtue of its high affinity for copper the Alzheimer's amyloid protein (A�) is capable of catalytic generation of neurotoxic H2O2 while its aggregation and deposition are...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics